JP2002511097A - ５−ｈｔ▲下６▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法 - Google Patents

５−ｈｔ▲下６▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法

Info

Publication number
JP2002511097A
JP2002511097A JP50818699A JP50818699A JP2002511097A JP 2002511097 A JP2002511097 A JP 2002511097A JP 50818699 A JP50818699 A JP 50818699A JP 50818699 A JP50818699 A JP 50818699A JP 2002511097 A JP2002511097 A JP 2002511097A
Authority
JP
Japan
Prior art keywords
methoxy
benzenesulfonamide
piperazin
methylpiperazin
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP50818699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002511097A5 (enExample
Inventor
ブロミッジ，スティーブン・マーク
モス，スティーブン・フレデリック
Original Assignee
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714530.4A external-priority patent/GB9714530D0/en
Priority claimed from GBGB9724530.2A external-priority patent/GB9724530D0/en
Application filed by スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー filed Critical スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー
Publication of JP2002511097A publication Critical patent/JP2002511097A/ja
Publication of JP2002511097A5 publication Critical patent/JP2002511097A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
JP50818699A 1997-07-11 1998-07-09 ５−ｈｔ▲下６▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法 Ceased JP2002511097A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9714530.4 1997-07-11
GBGB9714530.4A GB9714530D0 (en) 1997-07-11 1997-07-11 Novel compounds
GB9724530.2 1997-11-19
GBGB9724530.2A GB9724530D0 (en) 1997-11-19 1997-11-19 Novel compounds
PCT/EP1998/004973 WO1999002502A2 (en) 1997-07-11 1998-07-09 Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation

Publications (2)

Publication Number Publication Date
JP2002511097A true JP2002511097A (ja) 2002-04-09
JP2002511097A5 JP2002511097A5 (enExample) 2006-01-05

Family

ID=26311860

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50818699A Ceased JP2002511097A (ja) 1997-07-11 1998-07-09 ５−ｈｔ▲下６▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法

Country Status (20)

Country Link
US (1) US6316450B1 (enExample)
EP (1) EP0994862B1 (enExample)
JP (1) JP2002511097A (enExample)
KR (1) KR20010021643A (enExample)
CN (1) CN1087294C (enExample)
AR (1) AR013199A1 (enExample)
AT (1) ATE296811T1 (enExample)
AU (1) AU736256B2 (enExample)
BR (1) BR9810991A (enExample)
CA (1) CA2296033A1 (enExample)
DE (1) DE69830405T2 (enExample)
ES (1) ES2244082T3 (enExample)
HU (1) HUP0003073A3 (enExample)
IL (1) IL133870A0 (enExample)
NO (1) NO20000108L (enExample)
NZ (1) NZ501258A (enExample)
PL (1) PL338016A1 (enExample)
TR (1) TR200000073T2 (enExample)
TW (1) TW470743B (enExample)
WO (1) WO1999002502A2 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505559A (ja) * 2002-10-18 2006-02-16 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６受容体親和性を持つ４−ピペラジニルベンゼンスルホニルインドール
JP2006515341A (ja) * 2003-03-03 2006-05-25 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６調節物質として使用するための２，５−および２，６−置換テトラヒドロイソキノリン
JP2006519812A (ja) * 2003-03-11 2006-08-31 グラクソ　グループ　リミテッド フェニルスルホン誘導体およびｃｎｓ障害の治療におけるその使用
JP2007537275A (ja) * 2004-05-12 2007-12-20 ケモセントリックス， インコーポレイテッド アリールスルホンアミド
JP2009504633A (ja) * 2005-08-12 2009-02-05 スヴェン・ライフ・サイエンシズ・リミテッド 機能性５−ｈｔ６リガンドとしてのアミノアリールスルホンアミド誘導体
JP2010530875A (ja) * 2007-06-22 2010-09-16 ケモセントリックス， インコーポレイテッド Ｎ−（２−（ヘタリール）アリール）アリールスルホンアミドおよびｎ−（２−（ヘタリール）ヘタリール）アリールスルホンアミド
JP2012525354A (ja) * 2009-04-30 2012-10-22 アボット ゲーエムベーハー ウント カンパニー カーゲー セロトニン５−ｈｔ６受容体の調節に応答する障害を処置するのに好適なｎ−フェニル−（ピペラジニルまたはホモピペラジニル）−ベンゼンスルホンアミドまたはベンゼンスルホニル−フェニル−（ピペラジンまたはホモピペラジン）化合物
JP2015519319A (ja) * 2012-04-27 2015-07-09 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 新規化合物

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6500865B1 (en) 1998-07-31 2002-12-31 Eli Lilly And Company Sulfonamide derivatives
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US6586592B2 (en) 2000-06-20 2003-07-01 Pharmacia & Upjohn Company Bis-arylsulfones
PE20020063A1 (es) 2000-06-20 2002-01-30 Upjohn Co Bis-arilsulfonas como ligandos del receptor de 5-ht
SE0002739D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New use
US6399617B1 (en) * 2000-07-21 2002-06-04 Biovitrum Ab Use
GB0021450D0 (en) * 2000-08-31 2000-10-18 Smithkline Beecham Plc Novel compounds
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US6849644B2 (en) 2000-11-21 2005-02-01 Smithkline Beecham P.L.C. Isoquinoline derivatives useful in the treatment of CNS disorders
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
MXPA03010232A (es) 2001-05-11 2004-03-16 Biovitrum Ab Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
CN100457726C (zh) 2001-06-11 2009-02-04 比奥维特罗姆股份公开公司 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ⅱ型糖尿病的药物的应用
RU2268884C2 (ru) 2001-08-10 2006-01-27 Ф.Хоффманн-Ля Рош Аг Арилсульфонильные производные, обладающие сродством к рецептору 5-ht6, и способ их получения
RS44204A (sr) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
EP1461327A1 (en) * 2001-11-22 2004-09-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL161154A0 (en) * 2001-11-22 2004-08-31 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2007205749B2 (en) * 2001-11-22 2009-04-23 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EA200400707A1 (ru) 2001-11-22 2004-10-28 Биовитрум Аб Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
PL371344A1 (en) * 2002-02-13 2005-06-13 Glaxo Group Limited Benzenesulfonamide derivatives as antipsychotic agents
WO2003068732A2 (en) * 2002-02-13 2003-08-21 Glaxo Group Limited Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds
US20050090485A1 (en) * 2002-02-13 2005-04-28 Bromidge Steven M. 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders
GB0204720D0 (en) * 2002-02-28 2002-04-17 Glaxo Group Ltd Novel use
AR039127A1 (es) * 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
UA76877C2 (uk) 2002-05-13 2006-09-15 Ф.Хоффманн-Ля Рош Аг Похідні бензоксазину як 5-нт6 модулятори і їх застосування
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
EP1897881A3 (en) 2002-06-20 2009-03-18 Biovitrum AB (publ) Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
US20070021466A1 (en) * 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7227035B2 (en) * 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
TWI289141B (en) * 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050201965A1 (en) * 2004-03-11 2005-09-15 The Procter & Gamble Company Personal cleansing compositions
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
EP1799306B1 (en) 2004-09-30 2011-02-23 F. Hoffmann-La Roche AG Compositions and methods for treating cognitive disorders
EP1695971A1 (en) * 2004-12-30 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Substituted phenyl-piperazine compounds, their preparation and use in medicaments
AR054044A1 (es) * 2005-05-23 2007-05-30 Astrazeneca Ab Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad.
AR054363A1 (es) * 2005-05-23 2007-06-20 Astrazeneca Ab Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6
US7923566B2 (en) 2005-08-16 2011-04-12 Suven Life Sciences Limited Alternative process for the preparation of losartan
WO2007075895A2 (en) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2007133580A2 (en) * 2006-05-09 2007-11-22 Zelos Therapeutics, Inc. Use of pth (1-31) and optionally g-csf for hematopoietic stimulation
CN101553467B (zh) 2007-01-08 2011-12-07 苏文生命科学有限公司 5-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途
EP2120950B1 (en) * 2007-03-21 2012-07-04 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain
CL2008000986A1 (es) 2007-04-06 2008-10-17 Neurocrine Biosciences Inc COMPUESTO DERIVADO DE HETEROCICLOS DE NITROGENO, AGONISTAS DEL RECEPTOR GnRH; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO PARA TRATAR UNA AFECCION RELACIONADA CON LAS HORMONAS SEXUALES, ENDOMETRIOSIS, DISMENORREA, ENFERMEDAD DE OV
MX2009010828A (es) 2007-04-06 2009-10-29 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y metodos relacionados con los mismos.
AU2008246947B2 (en) 2007-05-03 2011-03-31 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands
CA2703157C (en) 2007-10-26 2013-02-05 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-ht6 ligands
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
EP2103596A1 (en) 2008-03-18 2009-09-23 Laboratorios Del. Dr. Esteve, S.A. Process for the preparation of N-(phenylethyl) anilines salts and solvates thereof useful as serotonin 5-HT6 antagonists
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
MX2011002884A (es) 2008-09-17 2011-04-21 Suven Life Sciences Ltd Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6.
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
MX2011011515A (es) 2009-04-30 2012-01-30 Abbott Gmbh & Co Kg Compuestos de bencensulfonanilida adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
CA2759491A1 (en) 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg. Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
AU2010276215A1 (en) * 2009-07-21 2012-02-16 Auckland Uniservices Limited Heteroaryl benzamides, compositions and methods of use
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
MX2012007783A (es) 2010-01-05 2012-10-03 Suven Life Sciences Ltd Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
GB201002563D0 (en) 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012059432A1 (en) * 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
US9708276B2 (en) 2011-10-12 2017-07-18 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
CA2924527C (en) 2013-09-20 2022-07-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate cancer
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
CN104557664B (zh) * 2013-10-19 2020-01-21 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
KR20160068799A (ko) * 2013-10-25 2016-06-15 글락소스미스클라인 엘엘씨 신규 화합물
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
EP3134392B1 (en) * 2014-04-19 2019-01-02 Sunshine Lake Pharma Co., Ltd. Sulfonamide derivatives and pharmaceutical applications thereof
CN105367474A (zh) * 2014-08-12 2016-03-02 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用
CN104529866A (zh) * 2014-12-12 2015-04-22 广东东阳光药业有限公司 吲哚类衍生物及其在药物上的应用
CN104496987B (zh) * 2014-12-12 2016-03-02 广东东阳光药业有限公司 取代杂环类化合物及其在药物上的应用
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
HK1260897A1 (zh) * 2015-08-21 2019-12-27 Portola Pharmaceuticals, Inc. 使用四氢异喹啉小分子来结合并调节pcsk9的蛋白活性的组合物和方法
EP3337788A4 (en) 2015-08-21 2019-03-27 Portola Pharmaceuticals, Inc. PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN / -KEXIN TYPE 9 P (CSK9) MODULATORS AND THEIR USE
WO2017034994A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
CN111517963A (zh) * 2020-06-02 2020-08-11 杭州福莱蒽特科技有限公司 环保型2，6-二氯-4-硝基苯胺的制备方法
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2442851A1 (de) * 1974-09-06 1976-03-18 Hoechst Ag Basisch substituierte 3-sulfamoylbenzoesaeurederivate und verfahren zu ihrer herstellung
US5169430A (en) * 1991-08-09 1992-12-08 Uniroyal Chemical Company, Inc. Benzenesulfonamide derivatives and methods for their production
DE69418045T2 (de) 1993-08-06 1999-10-07 Smithkline Beecham P.L.C., Brentford Amidderivate als 5ht1d rezeptor antagonisten
FI935373A0 (fi) * 1993-12-01 1993-12-01 Iws International Inc Kopplingsstycke eller koppling foer ledning
US5801170A (en) 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
GB9325827D0 (en) * 1993-12-17 1994-02-23 Smithkline Beecham Plc Compounds
WO1997007120A1 (en) 1995-08-11 1997-02-27 Smithkline Beecham Plc Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht1d receptor antagonists
FR2740134B1 (fr) 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
JP2000504677A (ja) * 1996-02-09 2000-04-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ７レセプター・アンタゴニスト用のスルホンアミド誘導体
US5939451A (en) 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
CA2274055A1 (en) 1996-12-19 1998-06-25 Smithkline Beecham P.L.C. N-piperazin-1-ylphenyl-benzamide derivatives
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505559A (ja) * 2002-10-18 2006-02-16 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６受容体親和性を持つ４−ピペラジニルベンゼンスルホニルインドール
JP2006515341A (ja) * 2003-03-03 2006-05-25 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６調節物質として使用するための２，５−および２，６−置換テトラヒドロイソキノリン
JP2006519812A (ja) * 2003-03-11 2006-08-31 グラクソ　グループ　リミテッド フェニルスルホン誘導体およびｃｎｓ障害の治療におけるその使用
JP2007537275A (ja) * 2004-05-12 2007-12-20 ケモセントリックス， インコーポレイテッド アリールスルホンアミド
JP2009504633A (ja) * 2005-08-12 2009-02-05 スヴェン・ライフ・サイエンシズ・リミテッド 機能性５−ｈｔ６リガンドとしてのアミノアリールスルホンアミド誘導体
JP2010530875A (ja) * 2007-06-22 2010-09-16 ケモセントリックス， インコーポレイテッド Ｎ−（２−（ヘタリール）アリール）アリールスルホンアミドおよびｎ−（２−（ヘタリール）ヘタリール）アリールスルホンアミド
JP2014193916A (ja) * 2007-06-22 2014-10-09 Chemocentryx Inc Ｎ−（２−（ヘタリール）アリール）アリールスルホンアミドおよびｎ−（２−（ヘタリール）ヘタリール）アリールスルホンアミド
JP2012525354A (ja) * 2009-04-30 2012-10-22 アボット ゲーエムベーハー ウント カンパニー カーゲー セロトニン５−ｈｔ６受容体の調節に応答する障害を処置するのに好適なｎ−フェニル−（ピペラジニルまたはホモピペラジニル）−ベンゼンスルホンアミドまたはベンゼンスルホニル−フェニル−（ピペラジンまたはホモピペラジン）化合物
JP2015519319A (ja) * 2012-04-27 2015-07-09 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 新規化合物

Also Published As

Publication number Publication date
CN1087294C (zh) 2002-07-10
HUP0003073A3 (en) 2002-10-28
ATE296811T1 (de) 2005-06-15
NZ501258A (en) 2001-07-27
HUP0003073A2 (hu) 2001-01-29
US6316450B1 (en) 2001-11-13
BR9810991A (pt) 2000-08-08
IL133870A0 (en) 2001-04-30
CN1261883A (zh) 2000-08-02
NO20000108D0 (no) 2000-01-10
KR20010021643A (ko) 2001-03-15
DE69830405T2 (de) 2006-01-26
NO20000108L (no) 2000-01-10
DE69830405D1 (de) 2005-07-07
WO1999002502A3 (en) 1999-06-03
EP0994862A2 (en) 2000-04-26
PL338016A1 (en) 2000-09-25
TW470743B (en) 2002-01-01
WO1999002502A2 (en) 1999-01-21
TR200000073T2 (tr) 2000-06-21
AU9257898A (en) 1999-02-08
AR013199A1 (es) 2000-12-13
EP0994862B1 (en) 2005-06-01
CA2296033A1 (en) 1999-01-21
AU736256B2 (en) 2001-07-26
ES2244082T3 (es) 2005-12-01

Similar Documents

Publication Publication Date Title
US6316450B1 (en) Compounds
US7977337B2 (en) Quinoline derivatives and their use as 5-HT6 ligands
US6025367A (en) Sulfonamide derivatives as 5HT7 receptor antagonists
US6548504B1 (en) Compounds
US20040242589A1 (en) 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
JP2003513085A (ja) 新規化合物
JP2002504484A (ja) 新規化合物
JP2004532240A (ja) ５−ｈｔ６受容体アンタゴニストとしてのベンゾ［ｄ］アゼピン誘導体
JP2005525332A (ja) ５−ｈｔ６受容体アフィニティーを有するスルホニル化合物
JP2006519812A (ja) フェニルスルホン誘導体およびｃｎｓ障害の治療におけるその使用
JP2007504114A (ja) ８−（１−ピペラジニル）キノリン誘導体およびｃｎｓ疾患の治療におけるそれらの使用
US6849644B2 (en) Isoquinoline derivatives useful in the treatment of CNS disorders
JP2002504549A (ja) ベンジルピペラジニル−およびベンジルピペリジニルエタノン誘導体、その調製、およびドーパミンｄ４受容体アンタゴニストとしてのその使用
JPH09506885A (ja) ５ｈｔ▲下１ｄ▼（抗うつ作用）活性を有するインドール、インドリンおよびキノリン誘導体
US20040034036A1 (en) N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide
KR20000022045A (ko) 5-ht-2c 수용체 길항제로 유용한 인돌린 유도체
KR20000005466A (ko) 신규한 n-아미노알킬-1-비페닐렌일-2-카르복스아미드;신규한 도파민 수용체 서브타입 특이적 리간드
MXPA00000414A (en) Novel compounds
JP2002526478A (ja) 非合成酵素阻害薬としてのアミノアルキル−３，４−ジヒドロキノリン誘導体
CZ200082A3 (cs) Sulfonamidové derváty, antagonisté receptoru 5- HT6, a způsob jejich přípravy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090303

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090728